id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15871 R65403 |
Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.62 [0.30;1.30] C excluded (control group) |
8/1,061 64/5,288 | 72 | 1,061 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15872 R65411 |
Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 0.85 [0.37;1.94] | 8/1,061 323/22,203 | 331 | 1,061 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10072 R46412 |
Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.80 [0.50;6.60] excluded (control group) |
4/621 7/2,108 | 11 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7807 R46413 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 2.50 [0.90;6.60] | 4/621 4,280/1,710,441 | 4,284 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7511 R46415 |
Huber-Mollema (Levetiracetam), 2019 | Diagnosis of autism spectrum disorder | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.72 [0.08;6.75] C | 1/30 4/88 | 5 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9963 R46416 |
Bjørk (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
2.42 [0.63;9.26] C excluded (control group) |
4/12 13/76 | 17 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9933 R46417 |
Bjørk (Levetiracetam) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
4.97 [1.49;16.49] C excluded (control group) |
4/12 6,907/75,497 | 6,911 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9961 R46418 |
Bjørk (Levetiracetam) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 4.54 [1.28;16.06] C | 4/12 27/272 | 31 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.73 [0.74;4.04] | 4,651 | 1,724 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, NOS; 3: Levetiracetam; 4: Levetiracetam) (Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9963, 9933, 10072, 15871